Intensity Therapeutics, Inc. (INTS)
| Market Cap | 12.93M +33.7% |
| Revenue (ttm) | n/a |
| Net Income | -10.69M |
| EPS | -5.82 |
| Shares Out | 2.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,059 |
| Open | 5.000 |
| Previous Close | 5.000 |
| Day's Range | 4.750 - 5.130 |
| 52-Week Range | 4.633 - 43.500 |
| Beta | 3.26 |
| Analysts | Buy |
| Price Target | 38.00 (+678.69%) |
| Earnings Date | May 7, 2026 |
About INTS
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INTS stock is "Buy." The 12-month stock price target is $38.0, which is an increase of 678.69% from the latest price.
News
Intensity Therapeutics reports Q1 EPS (96c), consensus ($1.09)
Cash and cash equivalents of $10.2M as of March 31. Lewis Bender, Founder, President, and CEO, stated, “The Company made excellent progress in the first quarter. We announced early data…
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to ...
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Company receives the Platinum Award for Innovator in Biotech Solutions Category SHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company...
Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker
Freedom Broker analyst Ilya Zubkov upgraded Intensity Therapeutics (INTS) to Buy from Hold with a price target of $20, down from $37.50. The firm says the company’s new financing has…
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027 IT-01 Study manuscript...
Intensity Therapeutics issued new patent in the US
Intensity Therapeutics (INTS) provided an update on its patent portfolio including the recent issuance in December 2025 of a new patent in the U.S. entitled “A Method of Treating Cancer”.
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
New US patent 12,496,345 strengthens the existing portfolio Patents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6 SHELTON, Conn., Ma...
Intensity Therapeutics price target adjusted to $30 at Alliance Global
Alliance Global adjusted the firm’s price target on Intensity Therapeutics (INTS) to $30 from $3.50 and keeps a Buy rating on the shares following Intensity’s 1-for-25 reverse stock split on…
Intensity Therapeutics provides update on INVINCIBLE-4 Study
Intensity Therapeutics (INTS) provided an update on the INVINCIBLE-4 Study. In September 2025, enrollment was paused by the company due to skin irritations observed in Cohort A. In early March…
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ("Cohort A") achieved a pathol...
Intensity Therapeutics regains Nasdaq compliance
Intensity Therapeutics (INTS) announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market that the company has regained compliance with Nasdaq Listin...
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics Inc trading halted, news pending
19:50 EST Intensity Therapeutics (INTS) Inc trading halted, news pending
Intensity Therapeutics announces reverse stock split
Intensity Therapeutics (INTS) announced that the board of directors of the Company approved a 1-for-25 reverse stock split of the Company’s common stock. The Reverse Split was approved by the…
Intensity Therapeutics Announces Reverse Stock Split
Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026 SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "th...
Intensity Therapeutics to ‘opportunistically raise additional capital’ in 2026
The company plans to maintain a disciplined operating approach in 2026 and will seek to opportunistically raise additional capital during 2026 to reinitiate patient enrollment and site activations in ...
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026 SHELTON, Conn., Jan. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasda...
Intensity Therapeutics to present two posters ay SABCS
Intensity Therapeutics (INTS) announces it will present two posters at the San Antonio Breast Cancer Symposium, SABCS, in San Antonio, TX being held at the Henry B. Gonzalez Convention Center.
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety 5...
Intensity Therapeutics granted 180-day extension to regain Nasdaq compliance
Intensity Therapeutics (INTS) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement…
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
SHELTON, Conn. , Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
SHELTON, Conn. , Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics reports Q3 EPS (6c) vs. (25c) last year
With the capital raised to date, the company has extended its cash runway until the end of the first quarter of 2027.
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate patient enrollment in the first quarter of ...
Intensity Therapeutics Transcript: Study Result
INT230-6, an intratumoral therapy combining SHAO, cisplatin, and vinblastine, showed high tumor retention, favorable safety, and promising efficacy in metastatic solid tumors, especially when ≥40% of tumor burden was injected. Median overall survival reached 12–19 months, with evidence of immune activation and abscopal effects.